Stipple Bio
Last verified 2026-04-30. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $100.0Mattributed |
|---|---|
| Latest round | series-a, $100.0M, 2026-04-01attributed |
| Founded | 2022 |
| Headquarters | Cambridge, US |
| Industry | bio |
| Stage | series-a |
| Website | stipplebio.com |
Stipple Bio is a biotech company developing targeted cancer therapies by identifying tumor-specific molecular epitopes that standard discovery methods miss. It serves cancer patients needing more precise therapeutic targeting. Its differentiator is a stippling method that maps subtle epitope differences invisible to traditional antibody discovery.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-01 | series-a | $100.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $100.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $100.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | stipplebio.com, read 2026-04-30 |
| Description | self-reported | stipplebio.com, read 2026-04-30 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.